Pomerantz Law Firm Investigates Potential Securities Fraud Involving Cybin Inc.

The legal landscape surrounding the investment community is forever changing, and recently, Pomerantz LLP has stepped into the spotlight by investigating possible claims for investors of Cybin Inc. (NYSE: CYBN). This investigation follows concerning developments regarding the company's leadership and operational practices.

Background of Cybin Inc.

Cybin Inc. is a company focused on the groundbreaking field of psychedelic medicine, which has shown promise in addressing various mental health issues. However, the recent resignation of Doug Drysdale as CEO has raised eyebrows among investors and analysts alike, leading to concerns over the company's transparency and stability. On September 2, 2025, Cybin announced that Drysdale would step down from his position. This unexpected leadership change was met with immediate market reactions, evidenced by a significant drop in stock price, plunging $1.24 or approximately 16.58%, closing at $6.24 per share on the same day.

What This Investigation Entails

Pomerantz LLP, recognized for its work in corporate, securities, and antitrust class actions, has begun probing whether Cybin and certain members of its management team may have engaged in securities fraud or other unlawful business activities prior to and following this announcement. Investors are being urged to come forward to help ascertain the validity of these claims.

The investigation will closely examine statements made by Cybin's executives and any potential discrepancies that may exist in their communications concerning the valuation of securities, which might have misled shareholders.

A Legacy in Investor Advocacy

Founded by Abraham L. Pomerantz, known as the pioneer of the class action bar, the firm has fought for victim's rights for over 85 years. They have successfully recovered vast sums for shareholders in numerous precedents, reinforcing their status as one of the top firms in this area. Past successes serve as a beacon of hope for investors currently facing uncertainty in the wake of Cybin's announcements.

Legal representatives from Pomerantz encourage current and former investors of Cybin Inc. to evaluate their options regarding the implications of the company's actions and to consider joining potential class action litigation by contacting Danielle Peyton at [email protected] or calling 646-581-9980, ext. 7980.

Conclusion

As this investigation unfolds, stakeholders are facing a crucial juncture that may significantly influence the direction of Cybin Inc. in the rapidly evolving psychedelic therapeutics sector. Investors will undoubtedly be watching closely as the firm's findings could set the stage for substantial legal ramifications or catalyst events impacting company policy and investor confidence.

For further details, feel free to check www.pomlaw.com to understand more about your rights as an investor and the importance of engaging with supporting legal counsel during such tumultuous times.